Transparency - a patient-centric view on radiopharmaceutical extravasations.

Frontiers in nuclear medicine (Lausanne, Switzerland) Pub Date : 2023-02-27 eCollection Date: 2023-01-01 DOI:10.3389/fnume.2023.1127692

Pam Kohl

{"title":"Transparency - a patient-centric view on radiopharmaceutical extravasations.","authors":"Pam Kohl","doi":"10.3389/fnume.2023.1127692","DOIUrl":null,"url":null,"abstract":"<p><p>Most radiopharmaceuticals are intravenously administered during nuclear medicine imaging or therapy procedures. When a nuclear medicine clinician delivers some or all of a radioactive drug into a patient's healthy tissue rather than the vein as intended, a patient experiences an extravasation. Radiopharmaceutical extravasations provide zero patient benefit and considerable potential downsides, depending on the severity of the extravasations. What nuclear medicine patients want and need regarding the administration of radiopharmaceuticals is transparency. And yet in the year 2023, little transparency exists regarding these extravasations. From the patient perspective, transparency regarding extravasations is essential to improving care, ensuring radiation protection, reducing health inequities, and untangling the deeply disturbing and irregular relationship between the nuclear medicine community and their regulating body, The U.S. Nuclear Regulatory Commission. Transparency is also critical to help address many other questions regarding radiopharmaceutical extravasations.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":" ","pages":"1127692"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440838/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in nuclear medicine (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fnume.2023.1127692","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Most radiopharmaceuticals are intravenously administered during nuclear medicine imaging or therapy procedures. When a nuclear medicine clinician delivers some or all of a radioactive drug into a patient's healthy tissue rather than the vein as intended, a patient experiences an extravasation. Radiopharmaceutical extravasations provide zero patient benefit and considerable potential downsides, depending on the severity of the extravasations. What nuclear medicine patients want and need regarding the administration of radiopharmaceuticals is transparency. And yet in the year 2023, little transparency exists regarding these extravasations. From the patient perspective, transparency regarding extravasations is essential to improving care, ensuring radiation protection, reducing health inequities, and untangling the deeply disturbing and irregular relationship between the nuclear medicine community and their regulating body, The U.S. Nuclear Regulatory Commission. Transparency is also critical to help address many other questions regarding radiopharmaceutical extravasations.

查看原文本刊更多论文

透明度——以患者为中心的放射性药物外渗观点

大多数放射性药物是在核医学成像或治疗过程中静脉注射的。当核医学临床医生将部分或全部放射性药物输送到患者的健康组织中，而不是按预期输送到静脉中时，患者会出现外渗。根据外渗的严重程度，放射性药物外渗对患者没有任何益处，也有相当大的潜在负面影响。核医学患者在放射性药物管理方面想要和需要的是透明度。然而，在2023年，这些挥霍几乎没有透明度。从患者的角度来看，外渗的透明度对于改善护理、确保辐射防护、减少健康不平等以及解决核医学界与其监管机构美国核监管委员会之间令人深感不安和不规则的关系至关重要。透明度对于帮助解决有关放射性药物外渗的许多其他问题也至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in nuclear medicine (Lausanne, Switzerland)

CiteScore

0.90

自引率

0.00%

发文量